These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
756 related articles for article (PubMed ID: 12670558)
1. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK; Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558 [TBL] [Abstract][Full Text] [Related]
2. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068 [TBL] [Abstract][Full Text] [Related]
3. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
4. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Freedland SJ; Csathy GS; Dorey F; Aronson WJ Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929 [TBL] [Abstract][Full Text] [Related]
5. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. Freedland SJ; Csathy GS; Dorey F; Aronson WJ J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909 [TBL] [Abstract][Full Text] [Related]
6. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Freedland SJ; Presti JC; Amling CL; Kane CJ; Aronson WJ; Dorey F; Terris MK; Urology; 2003 Apr; 61(4):736-41. PubMed ID: 12670557 [TBL] [Abstract][Full Text] [Related]
7. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ; Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931 [TBL] [Abstract][Full Text] [Related]
8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
9. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ; J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788 [TBL] [Abstract][Full Text] [Related]
10. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL; J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734 [TBL] [Abstract][Full Text] [Related]
11. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653 [TBL] [Abstract][Full Text] [Related]
12. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824 [TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
14. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203 [TBL] [Abstract][Full Text] [Related]
15. The correlation among the percentage of positive biopsy cores from the dominant side of prostate, adverse pathology, and biochemical failure after radical prostatectomy. Memis A; Ugurlu O; Ozden C; Oztekin CV; Aktas BK; Akdemir AO Kaohsiung J Med Sci; 2011 Aug; 27(8):307-13. PubMed ID: 21802641 [TBL] [Abstract][Full Text] [Related]
16. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy. Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061 [TBL] [Abstract][Full Text] [Related]
17. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
19. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631 [TBL] [Abstract][Full Text] [Related]
20. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]